BACKGROUND/AIMS: Few clinical trials conducted with cinacalcet have thoroughly addressed its effects of on bone metabolism. We assessed the effects of cinacalcet on bone markers in Japanese hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT). METHODS: 200 Japanese HD patients with intact PTH (iPTH) levels > or = 300 pg/ml were enrolled. The dose of cinacalcet was titrated from 25 up to 100 mg/day to achieve iPTH levels < or = 250 pg/ml for 52 weeks. RESULTS: At the end of the study visit, 57.8% of patients (115/199) had achieved iPTH levels < or = 250 pg/ml. Serum Ca, phosphorus (P) and Ca x P levels decreased rapidly and were maintained throughout the study. At week 52, all bone metabolic markers levels had decreased significantly from baseline. Although bone resorption markers gradually decreased throughout the study period, bone alkaline phosphatase significantly increased during the first 4 weeks and then gradually decreased. CONCLUSIONS: The time courses of changes in bone markers after cinacalcet treatment resembled those observed after surgical parathyroidectomy (PTx), sometimes described as the hungry bone syndrome, indicating that cinacalcet treatment induces a rapid recovery in bone response to calcium. In addition, long-term efficacy and safety of cinacalcet were also observed in Japanese patients undertaking long-term hemodialysis (167.0 +/- 81.4 months). 2008 S. Karger AG, Basel.
BACKGROUND/AIMS: Few clinical trials conducted with cinacalcet have thoroughly addressed its effects of on bone metabolism. We assessed the effects of cinacalcet on bone markers in Japanese hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT). METHODS: 200 Japanese HDpatients with intact PTH (iPTH) levels > or = 300 pg/ml were enrolled. The dose of cinacalcet was titrated from 25 up to 100 mg/day to achieve iPTH levels < or = 250 pg/ml for 52 weeks. RESULTS: At the end of the study visit, 57.8% of patients (115/199) had achieved iPTH levels < or = 250 pg/ml. Serum Ca, phosphorus (P) and Ca x P levels decreased rapidly and were maintained throughout the study. At week 52, all bone metabolic markers levels had decreased significantly from baseline. Although bone resorption markers gradually decreased throughout the study period, bone alkaline phosphatase significantly increased during the first 4 weeks and then gradually decreased. CONCLUSIONS: The time courses of changes in bone markers after cinacalcet treatment resembled those observed after surgical parathyroidectomy (PTx), sometimes described as the hungry bone syndrome, indicating that cinacalcet treatment induces a rapid recovery in bone response to calcium. In addition, long-term efficacy and safety of cinacalcet were also observed in Japanese patients undertaking long-term hemodialysis (167.0 +/- 81.4 months). 2008 S. Karger AG, Basel.
Authors: P Ureña; C Basile; G Grateau; B Lacour; A Vassault; A Bourdeau; R Bourdon; C Dubost; J Zingraff; T Drüeke Journal: Kidney Int Date: 1989-07 Impact factor: 10.612
Authors: L Darryl Quarles; Donald J Sherrard; Stephen Adler; Steven J Rosansky; Laura C McCary; Wei Liu; Stewart A Turner; David A Bushinsky Journal: J Am Soc Nephrol Date: 2003-03 Impact factor: 10.121
Authors: Geoffrey A Block; Kevin J Martin; Angel L M de Francisco; Stewart A Turner; Morrell M Avram; Michael G Suranyi; Gavril Hercz; John Cunningham; Ali K Abu-Alfa; Piergiorgio Messa; Daniel W Coyne; Francesco Locatelli; Raphael M Cohen; Pieter Evenepoel; Sharon M Moe; Albert Fournier; Johann Braun; Laura C McCary; Valter J Zani; Kurt A Olson; Tilman B Drüeke; William G Goodman Journal: N Engl J Med Date: 2004-04-08 Impact factor: 91.245
Authors: Natalie A Diepenhorst; Katie Leach; Andrew N Keller; Patricia Rueda; Anna E Cook; Tracie L Pierce; Cameron Nowell; Philippe Pastoureau; Massimo Sabatini; Roger J Summers; William N Charman; Patrick M Sexton; Arthur Christopoulos; Christopher J Langmead Journal: Br J Pharmacol Date: 2018-06-03 Impact factor: 8.739
Authors: Emanuel Zitt; Denis Fouque; Stefan H Jacobson; Fabio Malberti; Miroslav Ryba; Pablo Ureña; Marianne Rix; Bastian Dehmel; Nick Manamley; Marc Vervloet Journal: Clin Kidney J Date: 2013-04-11